Physician profile
John J King
NPI 1861505448
$74,156.86
in general payments reported to CMS, 2019-2025
42 companies · $24K in 2025
The $24K reported for 2025 was more than what 93% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,698 · 2020: $1,542 · 2021: $10K · 2022: $3,254 · 2023: $1,800 · 2024: $32K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $52K · Food and Beverage: $5,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $52,333.33 |
| Food and Beverage | $5,075.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $52,474.63 | 2023-2025 | Auryon Laser System 100-120 Vac, Auryon Laser System 100-120 Vac |
| Penumbra, INC. | $9,897.61 | 2020-2025 | Penumbra System, Indigo System |
| Boston Scientific Corporation | $1,700.35 | 2019-2025 | Eluvia, Jetstream Sc, Varithena Administration Pack |
| Novartis Pharmaceuticals Corporation | $1,328.86 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,107.75 | 2019-2025 | Wainua, Farxiga, Lokelma |
| Janssen Pharmaceuticals, INC | $890.31 | 2019-2024 | Xarelto |
| Medtronic, INC. | $762.81 | 2021-2025 | Onyx Frontier, Venaseal, Symplicity G3 |
| Merck Sharp & Dohme LLC | $701.34 | 2021-2025 | Verquvo, Capvaxive |
| Amgen INC. | $654.02 | 2020-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $648.11 | 2019-2023 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $593.46 | 2019-2025 | Jardiance |
| Philips North America LLC | $465.00 | 2019-2025 | Azurion 7 M20 |
| Abiomed | $413.05 | 2019-2025 | Impella |
| Terumo Medical Corporation | $395.48 | 2020-2025 | Navicross, Glidewire, Tr Band |
| Pfizer INC. | $307.69 | 2019-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $207.16 | 2021-2025 | Camzyos, Eliquis |
| Ge Healthcare | $175.60 | 2020-2021 | |
| Esperion Therapeutics, INC. | $173.08 | 2021-2025 | Nexletol |
| Medtronic Vascular, INC. | $165.05 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $156.42 | 2023-2024 | Inpefa |
| Abbott Laboratories | $153.95 | 2019-2025 | Cardiomems |
| Chiesi USA, INC. | $146.22 | 2019-2025 | Kengreal, Cleviprex |
| Regeneron Healthcare Solutions, INC. | $113.21 | 2019 | |
| Bridgebio Pharma, INC. | $66.95 | 2025 | Attruby |
| Sanofi-Aventis U.S. LLC | $60.70 | 2019 | |
| Teleflex LLC | $45.15 | 2025 | Supercross, Trapliner |
| Bard Peripheral Vascular, INC. | $44.00 | 2023-2024 | Rotarexs 6 F X 135 Cm |
| Scpharmaceuticals INC. | $35.89 | 2024 | |
| W. L. Gore & Associates, INC. | $33.73 | 2021-2025 | Gore Cardioform Septal Occluder |
| Cordis US Corp. | $33.48 | 2025 | Mynx Control |
| Cardiovascular Systems INC. | $29.49 | 2019 | |
| Gilead Sciences, INC. | $23.66 | 2019 | |
| Alnylam Pharmaceuticals INC. | $22.70 | 2022 | |
| Verge Medical, INC. | $19.57 | 2021 | |
| Axsome Therapeutics, INC. | $15.72 | 2025 | Auvelity |
| Cardiva Medical, INC. | $15.45 | 2022 | |
| Celonova Biosciences, INC. | $15.20 | 2019 | |
| Endologix LLC | $14.52 | 2019 | |
| Vifor Pharma, INC. | $13.04 | 2019 | |
| Amarin Pharma, INC. | $13.01 | 2021 | |
| Itamar Medical INC | $12.25 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.